Document Detail

Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma.
MedLine Citation:
PMID:  15578688     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Intrahepatic disease recurrence is observed frequently after locoregional therapies for patients with hepatocellular carcinoma (HCC). However, the indication for locoregional therapy is still unclear. To clarify the indication for locoregional therapy for small HCC tumors, the authors measured the distance of microsatellites from the main tumor and analyzed the relation between this distance and clinicopathologic factors. METHODS: The authors retrospectively analyzed 100 patients with small HCC tumors (</= 5 cm in dimension) treated by curative hepatectomy. A microsatellite was defined as invasion into the portal vein or intrahepatic metastasis, and the distance from the main tumor to the most distant microsatellite was determined under light microscopy. The current study investigated the relation between microsatellite distance (0 mm if none present, </= 5 mm, and > 5 mm) and clinicopathologic factors, as well as overall and disease-free survival rates after hepatectomy. RESULTS: Of the 100 patients, 46 had microsatellites with a mean distance of 9.9 mm (median, 5.0 mm). Of the clinicopathologic factors investigated, tumor grade and preoperative alpha-fetoprotein level significantly correlated with the presence of a microsatellite. Tumor size and distance to the microsatellite were significantly correlated. All but 1 tumor associated with a microsatellite distance > 5 mm was a high-grade tumor > 25 mm in greatest dimension. The overall survival rate of patients with a microsatellite distance of > 5 mm was lower than that of patients with a microsatellite distance < 5 mm. CONCLUSIONS: Locoregional therapy, including limited resection and ablation therapies, was appropriate for patients with low-grade HCC tumors or with tumors < 25 mm in diameter.
Atsushi Sasaki; Seiichiro Kai; Yukio Iwashita; Seitaro Hirano; Masayuki Ohta; Seigo Kitano
Related Documents :
23110018 - Plexiform angiomyxoid myofibroblastic tumor of the stomach: report of two cases and rev...
9110298 - Identical clonality of both components of mammary carcinosarcoma with differential loss...
9816248 - Allelic loss and replication errors at microsatellite loci on chromosome 11p in head an...
15900598 - Chromosome 1q loss of heterozygosity frequently occurs in sporadic insulinomas and is a...
18379348 - Tumor suppressor fus1 signaling pathway.
16863828 - Wilms' tumor arising within a mediastinal teratoma.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Cancer     Volume:  103     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2005-01-17     Completed Date:  2005-02-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  299-306     Citation Subset:  AIM; IM    
Copyright Information:
(c) 2004 American Cancer Society.
Department of Surgery I, Oita University Faculty of Medicine, Oita, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Analysis of Variance
Biopsy, Needle
Carcinoma, Hepatocellular / mortality*,  pathology*,  therapy
Chemoembolization, Therapeutic
Cohort Studies
Disease-Free Survival
Hepatectomy / methods
Liver Neoplasms / mortality*,  pathology*,  therapy
Microsatellite Repeats
Middle Aged
Multivariate Analysis
Neoplasm Invasiveness / pathology*
Neoplasm Staging
Retrospective Studies
Risk Assessment
Sensitivity and Specificity
Survival Analysis
Treatment Outcome
Tumor Markers, Biological / analysis*
Reg. No./Substance:
0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinom...
Next Document:  Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia.